|
|
||||||||||||||
|
|
|||||||||||||||
Department of
Pathology, University Hospital of Iceland, IS-101 Reykjavik, Iceland
Correspondence to: Dr Ingvarsson, siguring{at}rsp.is
Revised version received 26 November 1999;
Accepted for publication 14
December 1999
Chromosomal losses involving the short arm of chromosome 8 are
frequent in a variety of tumour types, including breast cancer, suggesting the presence of one or more tumour suppressor genes in this
region. In this study, we have used 11 microsatellite markers to
analyse loss of heterozygosity (LOH) at chromosome 8p in 151 sporadic
breast tumours and 50 tumours from subjects carrying the
BRCA2 999del5 mutation. Fifty percent of
sporadic tumours compared to 78% of BRCA2
linked tumours exhibit LOH at one or more markers at 8p showing that
chromosome 8p alterations in breast tumours from
BRCA2 999del5 carriers are more pronounced than in sporadic breast tumours. The pattern of LOH is different in the
two groups and a higher proportion of BRCA2
tumours have LOH in a large region of chromosome 8p. In the total
patient material, LOH of 8p is associated with LOH at other chromosome
regions, for example, 1p, 3p, 6q, 7q, 9p, 11p, 13q, 17p, and 20q, but
no association is found between LOH at 8p and chromosome regions 11q,
16q, 17q, and 18q. Furthermore, an association is detected between LOH
at 8p and positive node status, large tumour size, aneuploidy, and high
S phase fraction. Breast cancer patients with LOH at chromosome 8p have
a worse prognosis than patients without this defect. Multivariate
analysis suggests that LOH at 8p is an independent prognostic factor.
We conclude that chromosome 8p carries a tumour suppressor gene or
genes, the loss of which results in growth advantage of breast tumour
cells, especially in carriers of the BRCA2
999del5 mutation.
This article has been cited by other articles:
![]() |
M. E. Ray, Z. Q. Yang, D. Albertson, C. G. Kleer, J. G. Washburn, J. A. Macoska, and S. P. Ethier Genomic and Expression Analysis of the 8p11-12 Amplicon in Human Breast Cancer Cell Lines Cancer Res., January 1, 2004; 64(1): 40 - 47. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Wascher, K. T. Huynh, A. E. Giuliano, N. M. Hansen, F. R. Singer, D. Elashoff, and D. S. B. Hoon Stanniocalcin-1: A Novel Molecular Blood and Bone Marrow Marker for Human Breast Cancer Clin. Cancer Res., April 1, 2003; 9(4): 1427 - 1435. [Abstract] [Full Text] [PDF] |
||||
![]() |
M M de Jong, I M Nolte, G J te Meerman, W T A van der Graaf, J C Oosterwijk, J H Kleibeuker, M Schaapveld, and E G E de Vries Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility J. Med. Genet., April 1, 2002; 39(4): 225 - 242. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. U. Bender, M. Gutsche, S. Gläsker, B. Müller, G. Kirste, C. Eng, and H. P. H. Neumann Differential Genetic Alterations in von Hippel-Lindau Syndrome-Associated and Sporadic Pheochromocytomas J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4568 - 4574. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |